GAVISCON DOUBLE ACTION TABS
定性和定量构成
每个Gaviscon薄荷片含有海藻酸钠250毫克,碳酸氢钠133.5毫克和碳酸钙80毫克。
药物表格
咀嚼片。
一种灰白色至乳白色,略带斑驳的片剂。
临床细节
治疗适应症
治疗胃食管反流症状,如酸反流,胃灼热,消化不良(与反流有关),例如,饭后或怀孕期间或有反流性食管炎相关症状的患者。
行政与行政方法
口腔使用后,彻底咀嚼。
12岁及以上的成人和儿童:
饭后和睡前服用2至4片。
高龄:
此年龄组无需改变剂量。
禁忌
对于已知或怀疑对活性物质或任何赋形剂过敏的患者禁用该药品。
特殊警告和使用注意事项
四片剂量的钠含量为246mg(10.6mmol)。当建议采用高度限制的盐饮食时,应考虑到这一点,例如,在一些充血性心力衰竭和肾功能损害的病例中。
每个四片剂量含有320mg(3.2mmol)碳酸钙。在治疗高钙血症,肾钙质沉着症和复发性钙肾结石患者时需要注意。
由于其阿斯巴甜含量,该药用产品不应给予苯丙酮尿症患者。胃酸水平极低的患者可能会降低疗效。
Gaviscon
Generic name:
talimogene laherparepvec
Company: Amgen Inc.
QUALITATIVE & QUANTITATIVE COMPOSITION
Each Gaviscon Peppermint Tablet contains sodi- um alginate 250mg, sodium hydrogen carbonate 133.5 mg and calcium carbonate 80 mg.
PHARMACEUTICAL FORM
Chewable Tablet.
An off-white to cream, slightly mottled tablet.
CLINICAL PARTICULARS
Therapeutic Indications
Treatment of symptoms of gastro-oesophageal reflux such as acid regurgitation, heartburn, indiges- tion (related to reflux), for example, following meals or during pregnancy or in patients with symptoms related to reflux oesophagitis.
Posology & Method of Administration
For oral use, after being thoroughly chewed.
Adults and children 12 years and over:
Two to four tablets after meals and at bedtime.
Elderly:
No dose modifications necessary for this age group.
Contraindications
This medicinal product is contraindicated in patients with known or suspected hypersensitivity to the active substances or to any of the excipients.
Special warnings and precautions for use
The sodium content of a four-tablet dose is 246mg (10.6 mmol). This should be taken into account when a highly restricted salt diet is recommended, e.g. in some cases of congestive cardiac failure and renal impairment.
Each four-tablet dose contains 320 mg (3.2 mmol) of calcium carbonate. Care needs to be taken in treat- ing patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi.
Due to its aspartame content this medicinal product should not be given to patients with phenylketonuria. There is a possibility of reduced efficacy in patients with very low levels of gastric acid.
---------------------------------------------------------------
---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件(201882123403825.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------